National Bank of Canada
CODX

National Bank of Canada’s Co-Diagnostics CODX Stock Holding History

National Bank of Canada’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7
Closed -$250 – 2978
2024
Q3 		$250 Hold
7
– – ﹤0.01% 2515
2024
Q2 		$252 Hold
7
– – ﹤0.01% 2595
2024
Q1 		$220 Hold
7
– – ﹤0.01% 2634
2023
Q4 		$284 Hold
7
– – ﹤0.01% 2624
2023
Q3 		$206 Hold
7
– – ﹤0.01% 2696
2023
Q2 		$220 Hold
7
– – ﹤0.01% 2665
2023
Q1 		$294 Hold
7
– – ﹤0.01% 2625
2022
Q4 		$504 Hold
7
– – ﹤0.01% 2646
2022
Q3 		$1K Hold
7
– – ﹤0.01% 2577
2022
Q2 		$1K Buy
+7
New +$1.06K ﹤0.01% 2673

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAG
Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

National Bank of Canada's CODX Position: Q4 2024 in Review

National Bank of Canada sold out of Co-Diagnostics (CODX) in Q4 2024, closing a stake of 7 shares — an estimated $250 sold.

National Bank of Canada first reported a position in CODX in Q2 2022 and held it in 10 quarters. The position peaked at $1K in Q3 2022. 37 funds tracked by Wall St. Rank hold CODX as of Q4 2024.

  • National Bank of Canada reported no remaining Co-Diagnostics position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 7 Co-Diagnostics shares in Q4 2024, an estimated $250.
  • National Bank of Canada first reported a position in Co-Diagnostics in Q2 2022 and held it in 10 quarters.
  • National Bank of Canada's Co-Diagnostics position peaked at $1K in Q3 2022.
  • 37 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.